This review summarizes the most recent knowledge about ZIKV infection and pathogenesis and focuses on its impacts on male and female genital tracts, including the risks of sexual transmission and to pregnancy. The consequences of ZIKV infection for pregnancy planning and ART are also discussed.
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Introduction
Zika virus (ZIKV) infection is an emerging disease caused by ZIKV, an arthropod-borne virus, or arbovirus, transmitted by Aedes spp. mosquitoes. ZIKV belongs to the family Flaviviridae, as do dengue, yellow fever, St. Louis encephalitis, Japanese encephalitis and West Nile viruses. ZIKV was first isolated in 1947 from a febrile sentinel Rhesus macaque in the Zika Forest of Uganda, followed by isolation in 1948 in Aedes africanus mosquitoes in the same forest, suggesting the mosquito-borne transmission of the virus (Dick et al., 1952) . Between 1952, the date of the first human description, and the first epidemic in 2007 on a small island in Micronesia, fewer than 10 cases had been reported. In 2013, a large outbreak started in French Polynesia, spread through the Pacific Ocean region, and invaded most of the countries in the Americas.
ZIKV infection is predominantly a vector-borne disease and has long been considered a benign illness, likely asymptomatic in 50-80% of cases or causing mild symptoms (Duffy et al., 2009; Ioos et al., 2014; Aubry et al., 2017) . Actually, it is now clear that other, nonvector routes of ZIKV transmission may also occur, including congenital (Martines et al., 2016) , perinatal (Besnard et al., 2014) , sexual (McCarthy, 2016; d'Ortenzio et al., 2016) , blood transfusion , animal bite (Leung et al., 2015) and laboratory exposure (Simpson, 1964) . Moreover, severe clinical sequelae, such as GuillainBarré syndrome (GBS) (Heymann et al., 2016) and microcephaly (Rodriguez-Morales, 2016) , have also increasingly been associated with ZIKV. The World Health Organization (WHO) declared that the ZIKV infection is a public health emergency in February 2016 and initiated a strategic response, including recommendations for willing pregnant women. In this review, after a brief introduction to epidemiology and clinical and biological diagnosis, we will review the impacts of ZIKV infection on reproduction, risk of sexual transmission (from both males and females) and pregnancy and offspring. Finally, the management of pregnancy planning and ART in the context of ZIKV epidemics will also be discussed.
Epidemiology
Over the past 60 years, ZIKV has been observed circulating among African and Asian populations (Hayes, 2009 ), but has received little attention from the scientific community. Thus, a PubMed ® search identified only 69 publications about this virus between 1952 and 2013, compared to 66 publications in 2014 and 2015 and more than 2300 publications from 1 January 2016 to 31 March 2017. The first cases of human infection were identified through the detection of neutralizing antibodies against ZIKV in~13% of humans in Uganda in 1952 (Smithburn, 1952) . The virus was then discovered in three patients with jaundice in Nigeria in 1954 (MacNamara, 1954 . For almost half a century, ZIKV was limited to sporadic infections distributed throughout much of East and West Africa and Southeast Asia (Olson et al., 1981) . ZIKV emerged outside Asia and Africa for the first time in 2007. Thus, the first known epidemic occurred on Yap Island in Micronesia in the Pacific Ocean area, where 185 suspected cases were reported out of a population of 7391 inhabitants (Duffy et al., 2009 ). All of the reported cases were benign, and there was no report on central nervous system (CNS) impairment, possible foetopathy or consequences for pregnancy. The proportion of infected people in the population was estimated to be 73%, demonstrating a large number,~80%, of asymptomatic or paucisymptomatic cases. Only sporadic cases of ZIKV were related between 2007 , a large epidemic was reported in French Polynesia, with an estimated 19 000 symptomatic infections . Serosurveys conducted 18 months after the outbreak showed lower than expected disease prevalence rates (49%) and asymptomatic/symptomatic case ratios (1/1) in the general population but significantly different prevalence rates (66%) and asymptomatic/symptomatic ratios (1/2) in schoolchildren (Aubry et al., 2017) . During the Polynesian epidemic, 72 severe forms of ZIKV infections were described and associated for the first time with severe neurological manifestations, including 42 cases of GBS (Oehler et al., 2014; Cao-Lormeau et al., 2016) . No case of congenital cerebral malformations or dysfunction in foetuses and newborns, and no increase in the incidence of microcephaly in newborns were reported at that time. Nevertheless, retrospective studies were conducted in French Polynesia after the first descriptions of foetal impairment in Brazil in 2015, which secondarily found an increase in congenital cerebral malformations in newborns and foetuses during the epidemic Cauchemez et al., 2016 ). (Table I) . Proven recent local transmission has been reported in Angola, Cabo Verde and Guinea-Bissau in Africa as well as in Maldives in Asia. Some cases of ZIKV infection have been reported in travellers returning from Asian countries, such as Vietnam and Indonesia (Kwong et al., 2013; Meltzer et al., 2016) , but no active local transmission is currently described. Thus, any traveller with fever and/or rash returning from tropical areas (including but not limited to the areas at risk of transmission described above) may be candidate for ZIKV infection diagnostic testing, as are pregnant women and couples attempting to conceive and/or undergoing ART processes and coming from these areas, as low-level local transmission may exist.
Although there has been a recent effort at harmonization, the definition of affected/at-risk areas varies according to health authorities. There are significant knowledge gaps around ZIKV, and different countries do not have the same level of surveillance and diagnosis. Despite these issues, updated data concerning the geographical distribution of ZIKV are essential, and there is a need to better describe the epidemiology of ZIKV transmission in a given place and at a given time, to allow an appropriate assessment and relevant public health recommendations for residents and travellers, such as having a child or undergoing assisted reproduction treatments.
Diagnosis

Clinical diagnosis
The most commonly reported symptoms during ZIKV infection are a maculopapular rash (84-93%), fever (60-72%), arthralgia (65-67%), myalgia (44-60%) and conjunctival hyperaemia (initially described as conjunctivitis in the first publications) (33-63%) (Duffy et al., 2009; Daudens-Vaysse et al., 2016) . Other symptoms include headache (14%), retro-orbital pain (4-39%), oedema (4-12%), pruritus (8%), gastrointestinal symptoms (8-10%), asthenia (0-5%), lymphadenopathy (0-5%), ear, nose and throat symptoms (0-3%) and dizziness (0-1%). These symptoms are usually mild and last for 2-7 days. Thus, while the common clinical picture is quite similar to other arbovirus infections, such as dengue, some symptoms are more suggestive of ZIKV, such as conjunctival hyperaemia, rash and the frequency of the afebrile form. During the French Polynesia epidemic, atypical manifestations of neurological complications were reported, and these were secondarily confirmed during the epidemic in the Americas. GBS was the most frequently reported CNS impairment, but several others have been reported, such as meningoencephalitis, encephalopathy, encephalitis, acute myelitis and optic neuropathy (Mecharles et al., 2016; Rozé et al., 2016; Malta et al., 2017 Women are over-represented in several epidemiological publications, representing 62-70% of the total cases (Daudens-Vaysse et al., 2016; Hamer et al., 2017) . Substantial bias may exist, as pregnant women are systematically screened when living in or returning from epidemic areas due to the risk to the pregnancy, while the mild presentation of infection in men does not systematically lead to a biological diagnosis.
Biological diagnosis
The evolution of ZIKV infection is artificially divided into an acute phase, from Day 0 to Day 5 after the beginning of the symptoms, corresponding to the viraemic phase, and a convalescent phase, where viraemia usually disappears and IgM and IgG antibodies appear (Fig. 1) . During the acute phase, routine chemistry and complete blood counts are normal in most patients. Nevertheless, mild leukopaenia, thrombocytopaenia and elevated liver transaminases have been described, as usually described during dengue infection which is the most widespread arbovirus and the main differential diagnosis of ZIKV infection in those areas (Epelboin et al., 2013; Waggoner and Pinsky, 2016) .
The diagnosis of ZIKV infection relies on the detection of viral nucleic acids by RT-PCR during the acute phase and on the diagnosis of virus-specific immunoglobulin (Ig) M and IgG by ELISA during the convalescent phase (Fig. 1) . Other methods exist, such as viral culture and neutralizing antibodies, but their use is largely limited to research purposes.
Laboratory assays for acute specimens ZIKV can be identified by RT-PCR in ill patients during the acute phase. The period of viraemia is short, so WHO recommends RT-PCR testing of serum collected within 3 days of symptom onset or saliva samples collected during the first 5 days. Urine samples can be collected and tested up to 14 days after the onset of symptoms, as the virus has been observed to survive longer in the urine than in either saliva or serum.
Laboratory assays for convalescent specimens
Virus-specific IgM antibodies may be detectable within 3 days of the onset of illness. IgM antibodies typically persist for~12-12 weeks but may persist for longer. However, serological cross-reactivity may occur between ZIKV and other flaviviruses as well as between ZIKV and vaccines against flaviviruses, in people living in flavivirus-endemic areas. Thus, emphasis should be placed on molecular testing by RT-PCR of acute specimens received from individuals with clinically compatible illness (Centers for Disease Control and Prevention (CDC), 2017). Therefore, an IgM-positive result on a dengue or ZIKV IgM ELISA test should be considered indicative of a recent flavivirus infection. As with any diagnostic test, a negative ZIKV IgM or RT-PCR test result does not rule out infection with ZIKV.
Methods
The PubMed and EMBASE databases were inter-rogated using specific terms, such as 'ZIKV', 'transmission', 'male', 'female', fertility', 'pregnancy, 'semen', 'testis', 'ovary' and 'genital tract', up to 16 June 2017.
ZIKV in reproductive organs: genital shedding, sexual transmission and impact on fertility Before the onset of the current outbreak of ZIKV, a case of probable ZIKV transmission from a man to his female partner through unprotected sexual intercourse had already been reported (Foy et al., 2011) . The man, living in Colorado (USA), was infected during travel in Senegal in 2008 and, shortly after returning home, presented with symptoms of ZIKV infection together with symptoms of prostatitis and hematospermia. His wife, who had not travelled outside the USA during the past year, also presented with symptoms of ZIKV infection a few days after they had unprotected sexual intercourse. Both patients were found to be positive for ZIKV infection by serologic tests. This case strongly suggested that the transmission of infectious ZIKV by semen, but the presence of the virus in the ejaculate was not assessed. Four years later (Musso et al., 2015) , the presence of ZIKV was demonstrated in a man living in Tahiti (French Polynesia) who, in December 2013, presented with an episode of symptoms compatible with ZIKV infection, followed by a second episode 8 weeks later and then hematospermia 2 weeks after that. At that time, blood and semen samples were collected and tested for the presence of ZIKV RNA by RT-PCR. The results were negative in blood but positive in semen, with a high viral load (2.9 × 10 7 copies/ml). In a second set of samples (blood, urine and semen) collected 3 days later, RT-PCR was again positive in semen (1.1 × 10 7 copies/ml), positive in urine (3.8 × 10 3 copies/ml) and again negative in blood.
Since the beginning of the outbreak, the presence of ZIKV in genital fluids and its transmission through unprotected sex have been documented by several teams throughout the world. In a majority of cases, the identification of ZIKV in genital fluids relied on the detection of its RNA by RT-PCR, with different criteria used to define a positive sample for ZIKV (variable numbers of threshold cycles to obtain amplification and different numbers of copies per mL). Some studies reported a longitudinal follow-up of the detection of ZIKV RNA in genital fluids (mainly semen), but the isolation of infectious virus by culture in the Vero cell line was achieved in only a few cases. Although most studies were case reports (Musso et al., 2015; Arsuaga et al., 2016; Barzon et al., 2016; Deckard et al., 2016; d'Ortenzio et al., 2016; Dudley et al., 2016; Frank et al., 2016; Fréour et al., 2016; Harrower et al., 2016; Mansuy et al., 2016a; Matheron et al., 2016; Nicastri et al., 2016a,b; Prisant et al., 2016; Reusken et al., 2016; Visseaux et al., 2016; Gaskell et al., 2017; Froeschl et al., 2017; Murray et al., 2017; Penot et al., 2017; Russel et al., 2017) or included small numbers of patients (Mansuy et al., 2016b; Atkinson et al., 2017; Prisant et al., 2017) , several important notions about the genital shedding of ZIKV and the associated risks have emerged from these observations. In almost all reports, the patients who transmitted the virus or in whom ZIKV was detected in the genital compartment were males; only seven out of 24 original reports described genital shedding and/or virus transmission from an infected woman. Whether this asymmetry reflects true physiopathological differences between males and females remains to be confirmed and explained.
ZIKV in the male genital tract: presence and sexual transmission
In most of the studies listed above, the patients were living in an area of epidemic ZIKV transmission or returning from travel in an epidemic zone. Generally, the genital shedding of ZIKV (with or without sexual transmission) has been reported in symptomatic patients, but it has also been observed in asymptomatic patients Fréour et al., 2016) . ZIKV RNA can be found in semen at very high concentrations during the clinically symptomatic phase of the infection, up to 3 weeks after illness onset (d'Ortenzio et al., 2016).
In a majority of cases, the viral load was higher in semen than in blood or urine, with seminal concentrations 10 5 -fold the contemporary concentrations in blood in some instances Mansuy et al., 2016b) . This pattern, which has already been observed with HIV, indicates that local factors can increase the production of the virus in the male genital tract. These factors are currently not identified for ZIKV. More specifically, no association between detectable ZIKV RNA in semen and concomitant infection by another agent has been documented. After the acute phase, the seminal concentration of ZIKV RNA (when it has been observed) decreases with time, but the kinetics of this decrease show wide differences between individuals, and an important feature of ZIKV shedding in semen is the prolonged time during which it can persist while having disappeared from blood and other fluids, mainly urine and saliva. In most cases, ZIKV RNA was detected for a longer time in semen than in blood, except in a recent case (Froeschl et al., 2017) . Seminal shedding persisting more than 2 months has been noted in several cases (Arsuaga et al., 2016; Barzon et al., 2016; Gaskell et al., 2017; Harrower et al., 2016; Mansuy et al., 2016a,b; Nicastri et al., 2016a; Reusken et al., 2016; Atkinson et al., 2017; Froeschl et al., 2017; Fig. 2) beyond 3 months and up to 188 days in a few patients (Arsuaga et al., 2016; Barzon et al., 2016; Mansuy et al., 2016a,b; Nicastri et al., 2016a; Reusken et al., 2016; Gaskell et al., 2017) . Some of these patients were still under followup at the time of the report. Recently, a preliminary report provided new information about the persistence of ZIKV in several body fluids, including genital fluids (Paz-Bailey et al., 2017). The authors evaluated samples obtained from 150 participants (127 index cases and 23 household contacts) in whom ZIKV RNA was detected via RT-PCR assay in urine or blood at an enhanced arboviral clinical surveillance site. The frequency and duration of detectable ZIKV RNA in serum, urine, saliva, semen and vaginal secretions were estimated from the follow-up of newly infected participants (ZiPer cohort), who were identified among patients presenting with acute febrile illness to two emergency departments in Puerto Rico. All the participants involved in this cohort were symptomatic and tested positive for ZIKV infection by RT-PCR (except 4 of the 23 participants who were enroled as household contacts of index participants). Samples of different fluids were collected weekly during the first month and then at 2, 4 and 6 months. If ZIKV RNA was detected in any sample at week 4, additional samples were collected biweekly until all tested negative. Among the 55 male participants who provided at least one semen sample, 31 (56%) had detectable virus in at least one ejaculate. The maximum time for which detectable ZIKV RNA was observed in semen was 125 days after the onset of symptoms, and an estimated 4% of participants had detectable ZIKV RNA in semen beyond that time.
Nevertheless, ZIKV RNA detection does not always indicate the presence of infectious virus. A review of all available case reports and larger studies revealed that isolation of infectious virus by Vero cell culture was attempted in 31 ZIKV RNA-positive semen samples but was successful in only nine specimens (29.3%) (Arsuaga et al., 2016; Frank et al., 2016; Matheron et al., 2016; Nicastri et al., 2016a; Reusken et al., 2016; Gaskell et al., 2017; Froeschl et al., 2017; PazBailey et al., 2017) . This was not as late as the positive detection of ZIKV RNA, except in one patient with a semen sample collected 69 days after the onset of symptoms (Arsuaga et al., 2016) . Furthermore, Paz-Bailey's results suggested that semen should be considered infectious in patients for whom ZIKV RNA was detected within 37 amplification cycles using the CDC's RT-PCR protocol.
An important concern associated with the notion of persistent presence of ZIKV in semen is the possibility of intermittent shedding and, therefore, whether a negative RT-PCR result indicates the definitive clearance of the virus from the genital compartment. Among nine patients from six reports (Barzon et al., 2016; Harrower et al., 2016; Reusken et al., 2016; Atkinson et al., 2017; Gaskell et al., 2017; Froeschl et al., 2017) , from whom at least four semen samples were analysed before and beyond 2 months after the onset of symptoms, a succession of negative and positive RT-PCR results was observed in two men (Barzon et al., 2016; Froeschl et al., 2017) . Paz-Bailey et al.
(2017) also reported that intermittent ZIKV detection in the semen of three participants, but the timing in relation to illness onset was not precise. Obviously, this issue demands further investigation.
Other concerns particularly relevant to reproduction and ART are the origins of ZIKV in semen and the seminal components in which it can be associated. Until now, these questions have been largely ignored. One team reported that ZIKV RNA detection in the cell pellet obtained after semen centrifugation, but not in the seminal fluid, suggesting that the virus was perhaps present in cells rather than free in the seminal plasma. Which cells could harbour or carry ZIKV particles, and how could this association occur? Interestingly, three reports have indicated that ZIKV could be detected, isolated and sexually transmitted in the absence of spermatozoa. Two of these teams reported that ZIKV detection by RT-PCR and viral culture in the semen of vasectomized patients (Arsuaga et al., 2016; Froeschl et al., 2017) , with sexual transmission in one case (Arsuaga et al., 2016) , and one other team reported ZIKV detection by RT-PCR in the semen of a patient presenting with non-obstructive azoospermia (Fréour et al., 2016) . Taken together, these observations indicate that ZIKV could be present in semen as free particles or associated with cells, which could be seminal leucocytes or epithelial cells. However, another study using immunochemical detection showed the presence of ZIKV inside the spermatozoa of a patient who had presented with an initially high viral load (8.6 log copies/ml) and prolonged (up to 141 days) seminal shedding of ZIKV (Mansuy et al., 2016b) . ZIKV appeared to localize to the posterior part of the sperm head. The proportion of virus-positive spermatozoa was estimated to be 3.5% by screening semen smears using fluorescence microscopy. The authors suggested that Sertoli cells could have been involved in the transmission of the virus to sperm cells, which suggested an infection of testicular germ cells. However, they did not indicate from which ejaculate the spermatozoa were extracted. If they were extracted from a sample with a very high viral load, another possible explanation for the presence of ZIKV in spermatozoa could be the adsorption and penetration of viral particles during the epididymal transit. Regardless, these observations highlight the need for investigations dedicated to these questions.
Overall, the observations reported in these studies have provided useful information about the presence of ZIKV in semen and the large variability of its possible modalities and potentialities regarding its transmission through unprotected sex (Fig. 2 ). However, it should be noted that almost all the described patients had been investigated because they presented with symptoms of ZIKV or because sexual transmission was suspected. Nonetheless, approximately half of infections seem to be asymptomatic. Therefore, no estimation, even approximate, can be extrapolated from these reports regarding the frequencies and levels of genital shedding at different stages of the infection in people exposed to vectorial or sexual transmission or regarding the frequency of sexually transmitted infection. Indeed, only sporadic cases of sexual transmission may have been described because they occurred only in temperate countries, far from ZIKV outbreaks. In tropical countries where ZIKV epidemics rage, there is no means to differentiate vectorial from sexual transmission or to estimate the burden and proportion of the latter route of transmission.
ZIKV and male fertility (animal models)
To date, apart from two reported cases of hematospermia (Foy et al., 2011; Musso et al., 2015) , there are no published data on the impact of ZIKV infection on reproductive organs in humans.
The available information was obtained from experiments using mouse (Chan et al., 2016; Govero et al., 2016; Lazear et al., 2016; Ma et al., 2016; Rossi et al., 2016; Duggal et al., 2017; Uraki et al., 2017) and monkey (Osuna et al., 2016) models. Because, the replication of contemporary ZIKV seems inefficient in adult wild-type immunocompetent mice (Lazear et al., 2016) , experiments in male mice have used animals in which the antiviral immune response was impaired by different methods, allowing high levels of replication and wide dissemination of ZIKV in different organs and tissues. Overall, the results of these studies in mice were in agreement with regard to several points. In permissive conditions for ZIKV proliferation, high levels of ZIKV RNA and high titres of infectious ZIKV were found in the testis and epididymis in all tested animals (Chan et al., 2016; Ma et al., 2016; Rossi et al., 2016) . ZIKV persistence in the testis/epididymis could be observed weeks after clinical disease symptoms had resolved. The persistence of infectious ZIKV appeared to be briefer than the persistence of ZIKV RNA, but male-to-female transmission was observed, with evidence of foetal infection in resulting pregnancies (Duggal et al., 2017) . ZIKV infection of the testis and epididymisinduced severe histological and cellular damage, often in a highly inflammatory context with marked leucocyte infiltration. A significant decrease in testis and epididymis weight Ma et al., 2016; Uraki et al., 2017) and decreased plasmatic levels of testosterone Uraki et al., 2017) and inhibin B were also reported. However, there were discrepancies regarding the genital structures and cell types showing ZIKV infection and damage. Three studies (Chan et al., 2016; Duggal et al., 2017; Uraki et al., 2017) reported that ZIKV detection in prostate and/or seminal vesicles, with isolation of infectious virus from the seminal fluid of vasectomized males in one experiment (Duggal et al., 2017) , but another team reported negative results in these accessory genital glands . Differences also concerned the testicular structures and cells that were positive for ZIKV and/or were damaged: primarily interstitial tissue and Leydig cells were involved in one study (Uraki et al., 2017) , while the others found ZIKV together with inflammatory infiltrate in both seminiferous tubules and interstitial tissue associated with the loss of germ cells, Sertoli cells, peritubular cells and Leydig cells (Chan et al., 2016; Govero et al., 2016; Ma et al., 2016; Duggal et al., 2017) . The consequences of the orchitis induced by ZIKV for semen characteristics and fertilizing ability have been scarcely investigated. In one study , the counts of total and motile sperm harvested from the cauda epididymis were reduced. Moreover, decreased pregnancy rates and numbers of viable foetuses were observed in females mated with ZIKV-infected males. In macaques, ZIKV RNA was found at high levels in seminal plasma through testing of weekly collected semen samples (Osuna et al., 2016) . ZIKV RNA remained detectable until 3 weeks after it had been cleared from the blood. Infectious virus was isolated from all RNA-positive semen samples, with myeloid-lineage cells identified as major host cells.
To conclude, studies in male mice have shown active replication of ZIKV in several genital tissues weeks after clearance of the virus from the blood, and they have evidenced a high pathogenicity of ZIKV, especially on the testis and epididymis. Nevertheless, the major limitation of these studies is the use of mice with deficient antiviral immunity. The impact of ZIKV replication on genital tissues seems much less pronounced in immunocompetent macaques. Moreover, to the best of our knowledge, no case of clinical orchitis due to ZIKV has been reported in humans. Obviously, additional studies are needed to evaluate the impact of ZIKV on male reproductive organs and functions in humans and to precisely identify which cells in genital tissues can be primarily infected and could eventually carry ZIKV (Fig. 3) . Recently, it was reported that administration of a synthetic DNA vaccine encoding ZIKV pre-membrane and envelope (prME) completely protects mice against ZIKV-associated damage to the testes and sperm and prevents viral persistence in the testes following challenge with a contemporary strain of ZIKV (Griffin et al., 2017) . These data suggest that DNA vaccination merits further investigation as a potential means to prevent ZIKV persistence in the male reproductive tract, especially in patients with deficient immunity.
ZIKV in the female genital tract: presence and sexual transmission Female-to-male sexual transmission of ZIKV has recently been described (Davidson et al., 2016) . A woman engaged in one act of unprotected sexual intercourse the day she returned to New York City from travel to an area with an ongoing ZIKV epidemic. On the following day, she presented with symptoms of ZIKV infection. ZIKV RNA was detected in both serum and urine by RT-PCR performed on Day 3 after illness onset. The woman's male partner developed maculopapular rash, joint pain and conjunctivitis on Day 7. ZIKV sexual transmission from his female partner was suspected 3 days after the onset of his symptoms, as he had not travelled outside the USA during the previous year. On Day 9, ZIKV RNA was detected in his urine but not in his serum. ZIKV IgM antibodies were not detectable. The authors concluded that the woman was likely viraemic at the time of sexual intercourse. Virus present in vaginal fluids might have been transmitted to her male partner by contact with the urethral mucosa or undetected abrasions on his penis.
Very limited data (initially based on only a few cases reports) are available on the presence of ZIKV in the female genital tract and fluids, its clearance kinetics, and its possible intermittent excretion.
Nevertheless, these data are of high importance for both assessments of woman-to-man sexual transmission and understanding of motherto-child vertical transmission of ZIKV. Prisant et al. (2016) first reported the presence of ZIKV RNA in the genital tract of an infected woman. Contrary to findings in men, the presence of ZIKV in the genital tract may be more transient in women. ZIKV RNA was detected in endocervical swabs up to Day 3 (Penot et al., 2017) or 11 (Visseaux et al., 2016) and in vaginal swabs up to Day 13 (Nicastri et al., 2016b) or 14 (Murray et al., 2017) after the onset of symptoms. In a recent study of five women of childbearing age, ZIKV disappeared from genital secretions 3 weeks after the onset of symptoms, with no reappearance during a 3-month period (Prisant et al., 2017) . Only one study reported that the presence of infectious ZIKV particles in vaginal samples by isolation in cell culture 3 days after symptom onset in an HIV-infected woman (Penot et al., 2017) . That result coincided with a positive RT-PCR result from the same sample. The ZIKV Persistence (ZiPer) cohort study (Paz-Bailey et al., 2017) has greatly expanded our understanding of ZIKV shedding in female genital fluids. A total of 66 women were enroled in the ZiPer study, of whom five were pregnant. Few participants had detectable ZIKV RNA in vaginal or saliva secretions. Only one in 50 women (2%) had ZIKV RNA in vaginal secretions (at 3 days after symptom onset), which was no longer detectable after Day 7. Conversely, ZIKV RNA was present at one time point in saliva specimens from 15/147 (10.2%) men and women (data on gender unavailable). These rates were lower than those in serum and urine at any number of days after symptom onset. A limitation of this ZiPer study should be noted: although the authors could determine the limit of ZIKV RNA detection in semen, they were unable to evaluate it in saliva and vaginal secretions. Therefore, negative results should be interpreted with caution.
ZIKV and female fertility (animal models)
The extent and impact of ZIKV infection in the female gonads and genital tract have not been investigated in humans and scarcely in animal models. In immunosuppressed mice, broad viral dissemination with high viral loads in the ovary and uterus was observed 5 days after intraperitoneal virus inoculation. Another study using interferon α/β and γ receptor knock-out (KO) mice showed that ZIKV was detected in the uterus and vaginal wash of 10 out of 13 sexually infected females (Duggal et al., 2017) . Interestingly, the mean titre was higher in the uterus of the pregnant females (Chan et al., 2016) . By contrast, ZIKV was not detected in the uterus or vaginal wash of eight females infected through intraperitoneal inoculation (Rossi et al., 2016) . This finding suggested that viral dissemination could differ according to the route of infection. In addition to these studies in mice, two experiments were performed in macaques infected by subcutaneous ZIKV injection. In the first study (Dudley et al., 2016) , ZIKV RNA was detected in vaginal swabs from three females on Days 1 and/or 7 after inoculation but not on Days 14, 21 or 28. The second study reported only the sporadic and low-level presence of ZIKV RNA in vaginal swabs and limited numbers of ZIKV-infected cells in the uterus and ovary after the end of viraemia (Osuna et al., 2016) .
A preliminary synthesis of these case reports and experiments indicates that, in contrast to reports of prolonged detection of ZIKV RNA in semen, shedding in the female genital tract appears to be
What is to be known:
-Frequency among asymptomatic infected women and men -Factors increasing genital shedding -Origins: genital sites with active virus replication, association with sperm cells in men -Frequency of sexually acquired infection, maximum delay after infection of the transmitter partner
What is known:
-Possible in both sexes -Frequency among symptomatic infected -women (rare) -men (frequent, ~ one in two men)
ZIKV genital shedding
What is to be confirmed:
-Kinetics of virus clearance, maximum duration -variable in both sexes -early and transient in symptomatic women -early and prolonged, up to 120 days post illness in men -Isolation of infectious virus in both sexes -Intermittence: not evidenced in women, possible in male -Levels of viral load:
-Lower than serum viral load in women -Usually higher than serum viral load in men Figure 3 Male and female genital shedding: current knowledge and perspectives.
rare and of short duration. Ongoing surveillance is needed to determine the risk of transmission of ZIKV infection from a female to her sexual partner(s) (Fig. 3) .
Impact of ZIKV infection on pregnancy and offspring (vertical transmission, including hypothesis for the mechanisms of mother-to-child transmission)
Over 400 papers have been published on ZIKV and pregnancy since the first study reporting evidence of the perinatal transmission of ZIKV virus in French Polynesia in April 2014 (Besnard et al., 2014) . In late 2015, the Brazilian press reported a 'microcephaly outbreak', and Margaret Chan (WHO) mentioned a 'congenital ZIKV syndrome' (http: WHO, mediacentre). The WHO declaration of the ZIKV epidemic as a public health emergency probably accelerated and focused research on modes of transmission and foetal and neonatal anomalies associated with prenatal ZIKV infection (Rasmussen et al., 2016) . Almost 3000 cases of ZIKV-related microcephaly or other CNS defects have been recorded in 29 countries (Table I) . Over a year, progress was made in elucidating the transmission mode from mother to foetus and the main foetal malformations linked to ZIKV.
Maternal infection
There is no evidence that pregnant women are more susceptible to ZIKV infection than non-pregnant women (CitilDogan et al., 2016) . Symptoms reported are similar to those in non-pregnant women, with a large number of patients probably being completely asymptomatic or reporting mild symptoms (Chibueze et al., 2017) . No precise data exist on the specificity of the occurrence of severe manifestations, such as GBS, due to ZIKV during pregnancy .
Pregnancy outcome and offspring malformations
An unusual increase in congenital cerebral malformations in foetuses and newborns, including major brain lesions and severe microcephaly, severe cerebral lesions without microcephaly and brainstem dysfunction without visible malformations, was revealed in a retrospective review in French Polynesia (Cauchemez et al., 2016) following the Brazilian epidemic in October 2015 (Tetro, 2016) . Although several alternative explanations had been initially proposed in the media regarding the role of pesticides and insecticides, several publications have supported the association between ZIKV and microcephaly (Epelboin et al., 2016) . Thus, two cases of ZIKV genome detected in the amniotic fluid of foetuses with microcephaly have been reported (Calvet et al., 2016) . Several neonates with microcephaly who died in the first hours of life and two foetuses that spontaneously miscarried at 11 and 13 weeks of amenorrhoea (WA) tested positive for ZIKV (Martines et al., 2016) . Cerebral tissue and amniotic fluid from a foetus resulting from therapeutic interruption of pregnancy at 32 weeks for foetal hydrops (including severe microcephaly, hydranencephaly, hydrothorax, ascites and subcutaneous oedema) also tested positive for ZIKV RT-PCR (Sarno et al., 2016) . ZIKV was also found in the brain of a foetus with foetal malformations at ultrasound after an autopsy, after the Slovenian mother had presented with symptoms compatible with ZIKV infection during her pregnancy in Brazil (Mlakar et al., 2016) . In early March 2016, a Brazilian team published a study showing that 12% of 42 pregnant women with proven ZIKV infection during pregnancy had foetal abnormalities on obstetric ultrasound . To the best of our knowledge, except a few case reports, only a single longitudinal study including 134 ZIKV-positive and 73 ZIKVnegative pregnant women has reported rates of foetal loss, which were 7% in both groups . Thus, a higher risk of miscarriage or foetal death has not been clearly established. Among other types of non-neurological damage, intrauterine growth restriction (IUGR), oligoamnios, placental insufficiency or hydrops foetalis were reported in only a few studies (Besnard et al., 2014; Brasil et al., 2016) .
All cases described now make it possible to depict the 'congenital Zika Syndrome' which includes microcephaly, facial disproportionality, cutis girata, hypertonia/spasticity and hyperreflexia (Table II) . Abnormal neuroimaging includes calcifications, ventriculomegaly and lissencephaly Jouannic et al., 2016; Zare et al., 2017) . Hearing and visual abnormalities are also present (MirandaFilho et al., 2016) , with intraocular calcifications and microphthalmia (Ventura et al., 2016 ). An extensive description of congenital Zika syndrome was reported by Moore et al. 2017 , who defined five features that could be considered specific to ZIKV: severe microcephaly with a partially collapsed skull, thin cerebral cortices with subcortical calcifications, macular scarring and focal pigmentary retinal mottling, congenital contractures and marked early hypertonia and symptoms of extrapyramidal involvement.
The absolute risk of foetal microcephaly (and other birth defects) in women with ZIKV infection is difficult to define. Among the difficulties in identifying and counting cases, it should be noted that the definition of microcephaly is not universal and has changed in recent months, as in Brazil, leading to very broad estimates (Victora et al., 2016) . It was recently estimated that the absolute risk of a notified microcephaly case in Brazil during the ZIKV epidemic varied from 0.03 to 17.1% according to geographical area, the definition of microcephaly used and the infection rate (Jaenisch et al., 2017) . In the longitudinal Brazilian cohort, out of 134 ZIKV-positive women, only 59 agreed to ultrasound follow-up. At the end, 42% of the infants had abnormal findings during the first month of life, and 63% of those had an abnormal neurologic examination. Microcephaly was present in only 3.4% of cases, with two cases associated with IUGR and proportional microcephaly (this highlights the difficulty of head circumference measurement values). More recently, the US Zika Pregnancy Registry Collaboration group (Honein et al., 2017) showed that, out of 442 completed pregnancies with laboratory evidence of possible ZIKV infection during pregnancy, 6% involved a foetus or infant with evidence of a ZIKV-related birth defect (microcephaly with brain abnormalities). They also reported similar percentages of foetal/infant anomalies among pregnant women with symptomatic (6%) and asymptomatic (6%) infections. In a prospective study conducted in French Guiana in early 2016 that evaluated clinical and foetal ultrasound examinations of 301 pregnant women with biological confirmation of ZIKV infection and 399 pregnant women negative for ZIKV infection, the total number of foetuses with CNS anomalies was higher in the infected group than in the control group (9.1% vs 4.3%; RR = 2.11; 95% CI [1.18, 4.13]) (Pomar et al., 2017) . Anomalies of the corpus callosum and the presence of cerebral images of hyperechogenicity were also found to be significantly more common in the infected group. There was an increased risk of microcephaly (1.66%) in the infected group compared with the control group (0.25%), although this difference was not significant, unlike other signs of CNS and non-CNS foetal infection.
Finally, does the risk of birth defects (frequency and severity) vary according to the time of exposure during pregnancy? At first, it seemed that microcephaly developed when foetal infection occurred in early gestation; this was in concordance with experiments on animal models and induced pluripotent stem cells (iPSCs) showing an impairment of brain cell growth. Progressive alteration of the foetal head growth rate has been demonstrated (Sarno et al., 2016) . In Columbia, in December 2016, a temporal association between reported ZIKV infections and the occurrence of microcephaly was identified, with the peak number of reported microcephaly cases occurring~24 weeks after the peak of the ZIKV disease outbreak, suggesting that the period of highest risk was during the first and early second trimesters of pregnancy . Interestingly, at the time of the preliminary report , a majority of women exposed to ZIKV infection in their first and second trimesters did not deliver, and out of 1850 women exposed in the third trimester, no microcephaly was reported. Faria et al. (2016) showed that suspected microcephaly cases were best predicted by ZIKV incidence during week 17 of pregnancy. These observations were recently confirmed by a report that birth defects occurred in 11% (95% CI 6-19%) of pregnancies with maternal symptoms or exposure exclusively in the first trimester or periconceptional period, with no reports of birth defects among foetuses or infants with prenatal exposure to ZIKV infection only in the second or third trimester (Honein et al., 2017) . In a French Guianese cohort, when the mother was infected during the first or second trimester, there was a greater risk of more severe CNS anomalies and intrauterine foetal demise (Pomar et al., 2017) . A recent study found a decrease in the risk ratio for microcephaly from the first trimester (53.4 (95% CI 6.5-1061.2)) to the second (23.2 (95% CI 1.4-407.8)) and third trimesters (0 (95% CI 0-49.3)) (Chibueze et al., 2017 maternal infections, possible ZIKV-associated birth defects were reported in 8, 5, and 4% of infants or fetuses with maternal symptoms or positive laboratory results identified during the first, second, and third trimesters, respectively (www.cdc.gov/mmwr). However, with the increasing number of reported cases, it appears that even a late infection could lead to severe brain damage and neural impairment (Faria et al., 2016; Soares de Souza et al., 2016) .
Hypotheses for the mechanisms of embryo/ foetopathogenic impact of ZIKV Proving a link between ZIKV prenatal infection and microcephaly and other serious brain defects has not been easy; in early 2016, from the epidemiological data available, it was impossible to establish the true size of the surge in microcephaly. One of the explanations could be increased diagnosis due to the diagnostic criteria for microcephaly being relatively unspecific, as previously mentioned. The WHO, CDC in the USA, and Haut Conseil de la Santé Publique in France have now issued recommendations on how to diagnose microcephaly. Moreover, there is no easy-to-use and widely deployed test to diagnose ZIKV infection. Mlakar et al. (2016) were the first to demonstrate that ZIKV was present in the CNS tissues of a foetus with serious lesions. Although this finding was not sufficient to prove causality, case reports made the link stronger (Rubin et al., 2016; Driggers et al., 2016) . The presence of the ZIKV genome and anti-ZIKV IgM has also been shown in amniotic fluid from two pregnant Brazilian women, which suggested that the virus can cross the placental barrier (Calvet et al., 2016) . ZIKV can be found in amniotic fluid several months after infection in the first trimester . ZIKV has been identified in the placenta (Martines et al., 2016; Roberts and Frosch, 2016) and in amniotic epithelial cells . Studies using midand late-gestation human placentas and explants from first trimester chorionic villi have found ZIKV infection of many cell types (cytotrophoblasts, endothelial cells, fibroblasts and Hofbauer cells) suggesting multiple potential routes of vertical transmission (Ming et al., 2016; Tabata et al., 2016) . ZIKV can replicate in human placental trophoblasts without host cell destruction, serving as a likely permissive reservoir long after initial maternal exposure or viraemia . Nevertheless, it must be confirmed whether in-situ active ZIKV replication exists in the placenta distal from maternal infection, and the windows of susceptibility in both the placenta and the foetus need to be clarified.
In vitro models have helped explain the evident foetal neurotropism of ZIKV. ZIKV can infect human neural progenitor cells derived from iPSC . ZIKV increases cell death and dysregulates cell cycle progression, resulting in neural cell growth attenuation. Spinal cord defects and infection of multiple cell types in the retina have also been evidenced in ZIKV-infected mouse models (Ming et al., 2016) . At the molecular level, ZIKV infection leads to the downregulation of cell cycle genes and the upregulation of apoptosis genes . These findings, confirmed by others (Cugola et al., 2016; Garcez et al., 2016) , allowed the US CDC (Rasmussen et al., 2016) and WHO (Krauer et al., 2017) to declare that ZIKV causes microcephaly.
Overall, the causal relationship between ZIKV infection and adverse pregnancy and birth outcomes is now recognized, but many questions remain: the phenotype of 'congenital ZIKV infection' needs to be refined , as do factors that could modify the risk (such as co-infection, previous exposure to another related virus or genetic background) (Rasmussen et al., 2016) . Numerous questions remain regarding secondary infection, long-lasting immunity, and latent or late-onset complications in asymptomatic infected newborns, and accurate risk estimation is still impossible (Torjesen, 2016) . In September 2016, an international web registry for women exposed to ZIKV was launched to improve knowledge and care (Panchaud et al., 2016) .
Current management in pregnancy planning and ART in the context of ZIKV epidemics
Various actions have been implemented by authorities to assess and reduce the risk of ZIKV transmission to the foetus and consequences for foetal development. Despite some differences according to countries, the recommendations have often been convergent.
Authorities' plans and strategies at the European and international levels
The European Centre for Disease Prevention and Control (ECDC) works in partnership with national health protection bodies across Europe to develop continent-wide disease surveillance of emerging threats and early warning systems. According to its mandate, ECDC issued risk assessments associated with ZIKV epidemics in affected countries. The risk assessments evolved according to current evidence but took into account remaining uncertainties. The first guidance provided by ECDC was published in January 2016 (http: ECDC, 2016). Then, the US CDC activated its emergency operations centre to respond to the outbreak occurring in the Americas. CDC scientists with expertise in arboviruses, reproductive health, birth defects, developmental disabilities and travel health worked on developing laboratory tests to diagnose ZIKV (http: CDC, ZIKV diagnosis), tracking the spread of ZIKV, deciphering the links between ZIKV and congenital defects (http: CDC, birth defects) and investigating the persistence of ZIKV in semen. The CDC also reported cases of ZIKV (http: CDC, Zika) and provided guidance to healthcare providers and people living or travelling in areas with current outbreaks (http: CDC, ZIKV, travel). As noted above, the CDC set up a ZIKV pregnancy registry collecting information about adverse pregnancy outcomes to better inform clinical care and develop services for pregnant women infected with ZIKV. WHO provided periodically updated situation reports beginning in February 2016 (http:CDC, ZIKV, geo) and proposed a strategic response plan in July 2016 intended to be revised during the following 18 months (http: CDC, ZIKV, public health partners). WHO also created a specific ZIKV website (http: CDC, Zika) providing information on risk and general or technical guidance.
Public actions and recommendations have varied according the countries and the degree to which they were concerned by the ZIKV outbreak. In France, different national bodies have produced regular epidemiological reports about the epidemic situation in overseas departments affected by the epidemic, as well as prevention advice for populations and travellers. The Ministry of Health organized a mandatory declaration of infection, provided information about the risks related to ZIKV infection and alerted pregnant women not to travel to high-risk areas. Concerning ART, recommendations were published by the Biomedicine Agency (ABM) in relation with other French health authorities.
In the UK, the Human Fertilization and Emergency Act (HFEA) followed the ECDC risk assessments. Other professional societies have aligned with their authorities, such as the American Society for Reproductive Medicine (ASRM) and the CDC.
Diagnostic means
As previously described, different diagnostic tests are available to determine whether a person is or has been infected with ZIKV. The CDC and WHO recommended serological testing of any pregnant woman who might have been exposed to ZIKV within the past 3 months through travel, place of residence and/or sexual contact without protection but did not recommend testing for asymptomatic couples interested in attempting conception in which one or both partners had possible exposure to ZIKV. The WHO's testing combines RT-PCR and serology (IgM isolated). Further guidance on serological testing should be provided as more information becomes available.
Pregnancy planning recommendations
The severity of foetal impairment in pregnant women infected by ZIKV implies a priority to reduce the risk of infection in pregnant women and women of childbearing age through vector-borne and/or sexual transmission and to adapt preconception counselling. The CDC has provided clinical guidance for healthcare providers caring for women of reproductive age. For women and men with possible exposure through travel or sexual contact and who do not reside in an area with active transmission, the CDC recommends that women should be advised to wait to attempt conception. Women planning pregnancy should discuss the timing of pregnancy with healthcare providers. For women and men living in affected areas or with possible ZIKV exposure through travel or sexual contact, healthcare providers should recommend that men wait to attempt conception at least 6 months from symptom onset or the last exposure, and that women wait at least 8 weeks from symptom onset or the last exposure. Men should be counselled to correctly and consistently use condoms or abstain from sex during this time period if they are concerned about the possibility of transmitting ZIKV to their partners. These recommendations are aligned with the ECDC and WHO recommendations. However, although it is relatively easy to recommend that those living outside epidemic areas not travel to regions with ZIKV presence, this is almost impossible for residents. Furthermore, in the context of the ZIKV outbreak, it is important to highlight the disparity among different areas in access to information, contraception and prenatal care with the appropriate level of ultrasound and the option of termination in case of severe malformations, which is forbidden in some countries (Aiken et al., 2016) . In addition, the large numbers of paucisymptomatic infections, the acquaintance of populations with the signs of arboviral infections, and geographic difficulty accessing medical care units impair the possibilities of diagnosis (Epelboin et al., 2016) . Women are not well informed, and those living in poor and vulnerable areas have poor access to reproductive health and rights and are often living in areas exposed to ZIKV (Roa, 2016) .
Guidelines for pregnant women during ZIKV outbreaks
In case of pregnancy, various actions have been implemented by authorities to assess and reduce the risk of foetal infection by ZIKV transmission and the consequences for foetal development. The recommendations are codified, either in the case of the discovery of microcephaly or other brain anomalies in a foetus whose mother lives in an epidemic zone or has travelled there or if there is fear of maternal infection, symptomatic or not, in these two contexts. A multidisciplinary follow-up is organized, including serological assessment and ZIKV RT-PCR in blood and urine (with diagnosis of other arboviruses). Monthly ultrasound monitoring of the foetus is recommended. In case of lower cephalic biometry (<5th percentile), ultrasound and MRI examination of the foetal brain are mandatory. If needed, amniocentesis for viral testing of the amniotic fluid should be performed 3-4 weeks after the acute phase.
At birth, it is necessary to perform ZIKV RT-PCR on cord blood, urine and the placenta. ZIKV serological testing of children with confirmation of antibody specificity by sero-neutralization and paediatric monitoring and follow-up will be organized. More recent papers by Brazilian teams have emphasized the importance of systematic ophthalmic examination of neonates exposed to ZIKV in utero (MirandaFilho et al., 2016) .
ART recommendations
The CDC, ECDC and WHO recommendations do not directly address ART issues related to ZIKV outbreaks, but recommendations provided for women of childbearing age or planning pregnancy apply to the ART sector. In November 2016, in the light of the ECDC recommendations, the HFEA published a short guidance for travellers returning from affected areas. They should not try to conceive naturally, donate gametes or proceed with fertility treatment for 8 weeks and 6 months for female and male, respectively (http:hfea.gov.uk). Sperm donors who have been infected with ZIKV should be deferred from donation for 6 months unless the semen tests negative for ZIKV. According to the Food and Drug Administration (FDA) guidance, anonymous or directed donors of sperm, oocytes and embryos will be deemed ineligible if they have any of the following risk factors: medical diagnosis of ZIKV infection in the past 6 months, residence in or travel to an area with active ZIKV transmission within the past 6 months, or had sex with a male partner who, during the 6 months before this sexual contact, received a diagnosis of or experienced an illness consistent with ZIKV disease, or had travelled to an area of active ZIKV transmission (http:fda.gov). When using donated embryos, consideration should be given as to the potential exposure of the embryos to ZIKV. Finally, the emphasis is placed on the fact that sperm preparation process that has been shown to be effective for minimizing the risk of HIV transmission has not yet been demonstrated to be effective in preventing transmission of the ZIKV.
Some professional societies have proposed recommendations directly applicable to the management of ART. The ASRM developed guidelines with input from the CDC (http: asrm.org). For males or females with a positive viral RT-PCR test result, treatment of infertility should be deferred until (i) a subsequent RT-PCR re-test is negative on both the male and female and (ii) at least 6 months have passed for them from the time of the last positive result. For males or females without testing or with a negative RT-PCR test result, gamete or embryo cryopreservation have to be considered and quarantined until (i) a subsequent RT-PCR re-test is negative on both the male and female and (ii) at least 8 weeks have passed from the time of the gamete collection. For males not previously infected with the ZIKV who are planning travel to an area of active virus transmission, semen cryopreservation should be considered before travel, and testing for viral RNA by RT-PCR at the time of semen collection and within 1 week after return is recommended.
The French experience
The current ZIKV outbreak reached the French Territories of America (FTA) in January 2016. French health authorities were highly concerned by the impact of ZIKV on ART practice, which implies the responsibility of ART practitioners, for several reasons: (i) women living in these territories represent~2% of the French population of reproductive-age women, (ii) two centres in Guadeloupe and Martinique offer ART treatments and (iii) numerous people living in mainland France travel to these territories.
Although there have been no reported cases of ZIKV transmission through ART or non-partner gamete or embryo donation, these scenarios remain theoretically possible; risk assessment must be performed for people living in FTA or living in mainland France and wishing to travel to affected areas.
In February 2016, the ABM provided ART practitioners with guidelines on ART, fertility preservation and gamete donation in the context of ZIKV infection outbreaks (Agence de la Biomedecine, 2017). ABM requested that FTA ART centres postpone, as much as A serology test combining ZIKV IgM and IgG is performed 2 months after the end of ZIKV outbreak or man's return from an affected area. This serology is not necessary if previously diagnosed ZIKV infection. If negative, RT-PCR on SF is performed, after separation from sperm pellet. If negative, it allows ART in a non-viral circuit. If positive or if positive serology or diagnosed ZIKV infection, the couple can choose between postponing ART or sperm testing for ZIKV. In this option, sperm is separated from SF on density gradient and cryopreserved in straws in a viral risk IVF unit, for RT-PCR testing and eventual use. If both sperm and SF are negative, ART and fertility preservation can be performed without any specific process. If ZIKV is detected in SF but not in sperm, ART is allowed with the remaining cryopreserved sperm. If ZIKV is detected in both sperm and SF, the ART is postponed until the sperm preparation shows a negative RT-PCR result. ABM, Biomedicine Agency; SF, seminal fraction.
possible, any ART treatment until after the end of the epidemic. The objective was at first to avoid pregnancies in an area with a high risk of ZIKV infection and, second, to avoid using and storing gametes, embryos or gonadic tissues potentially infected with ZIKV. When delaying ART would severely impair its success, oocyte cryopreservation could be discussed. Moreover, fertility preservation in situations such as prior to cancer treatment remained possible with specific technical procedures. For residents of mainland France, prior to considering ART, fertility preservation or gamete donation, patients/donors must be questioned regarding the existence of specific exposure to ZIKV infection through travel and/ or sexual exposure based on ECDC maps and lists of affected areas. Due to the rapid progress of knowledge and changes in the epidemiological situation, the ABM recommendations regarding ART have been revised several times throughout 2016. Despite a very uncertain situation involving many unresolved issues, the successive guidelines aimed to limit public health risks while delivering general information to patients requesting ART, who should be strongly advised of the potential consequences for their offspring's health if ZIKV infection occurs during pregnancy and about all prevention measures. In January 2017, the fourth version was published to take into consideration the end of the outbreak in the FTA in late 2016 (ABM, 2017) .
These new recommendations took into account the residual risks of vector-borne or sexual transmission and, more generally, the risks to travellers from areas where ZIKV is present. To summarize, ART treatments may start again in FTA beginning 2 months after the end of the epidemic. Active follow-up of at-risk populations (pregnant women and neonates) is maintained. For people residing in the French mainland who have travelled to an at-risk area during the epidemic period, a delay of at least 2 months after the return is necessary before ZIKV screening is performed and the technical conditions of ART with regards to ZIKV risk are determined. In the current state of knowledge, determining a woman's ZIKV serology is not useful for defining modalities of ART management if sexual intercourse has been protected for at least 2 months and continues to be protected. However, it can be useful to know the initial status of the woman with regard to ZIKV infection before ART management and to make the patients aware of protective measures and pregnancy monitoring. ABM based its recommendations for ART management on the ZIKV infection status of the male patient, combining ZIKV serology (IgM and IgG) and RT-PCR testing of a semen sample ( Fig. 4 ; Huzly et al., 2016; Steinhagen et al., 2016) . If ZIKV serology and RT-PCR testing of semen are both negative, ART can be performed with no specific ZIKV-related measures. In case of positivity or previously diagnosed ZIKV infection, sperm preparation through selection on a density gradient and washing is applied. ZIKV RT-PCR is performed on seminal fluid and selected sperm, and only RT-PCR-negative sperm can be used for fertilization.Overall, recommendations regarding routine testing of non-pregnant women and in men before attempting conception, through ART or not, are heterogeneous depending on the country's availability of tests and the confidence in the results of these tests. Healthcare providers will have to follow evolving recommendations published by their national authorities.
Conclusion
The current ZIKV outbreak has been remarkable in its rapid expansion. In a few years, it has spread to over 50 countries or territories throughout the world, and it seems likely to reach African and Asian countries soon. During the last 2 years, the fear has emerged that ZIKV, considered harmless until recently, could have a strong impact on reproduction by combining severe embryo-foetal pathogenicity, the ability to be sexually transmitted and perhaps (although not documented to date in humans) the ability to impair fertility. Whether the epidemic is ending in many countries in the Americas, it is difficult to predict the further evolution in this area and the spread to other continents.
In the face of these risks, which were perhaps especially threatening because they were poorly estimated, public health and scientific authorities have elaborated strategies and recommendations, largely based on a precautionary principle, with the initial aim of preventing the risk of ZIKV infection during pregnancy. Thus, postponing any pregnancy plans, especially in an epidemic area, has been a consensual recommendation.
In the next few years, a major improvement will be to precisely determine the actual frequencies in humans of the different pathogenic potentialities that have been attributed to ZIKV and their respective consequences for fertility and offspring. Thus, the situation will continue to rapidly evolve. Practitioners caring for people wishing to conceive should remain aware of the changes concerning epidemic areas, main screening, diagnostic methods and recommendations regarding sexuality and procreation to be able to provide adequate information to their patients (Supplementary Table 1) .
ART practitioners have invested in evolving knowledge about the epidemic and the consequences of ZIKV infection to better control the risks of the medicalization of conception for the child, as in other contexts, such as a genetic pathology of one member of the couple. Consideration of risks to the foetus involves multidisciplinary decisions (Supplementary Table 1 ).
Other essential advances will be the development of strategies and vaccines to stop the spread of the virus and prevent its most severe effects. Candidates ZIKV vaccines have shown protective efficacy in preclinical studies carried out in animal models, and several vaccines have entered clinical trials. This collective experience should be used to better anticipate responses to future outbreaks of infectious agents that are transmissible through several routes.
Supplementary data
Supplementary data are available at Human Reproduction Update online.
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